https://novapharmanews.com/eu/news/eu-pharma-package-exclusivity-timelines-what-innovators-can-do-now 2026-06-17T07:41:18.208Z NovaPharmaNews en 2026-06-17T04:37:32.376Z EU Pharma Package exclusivity timelines: what innovators can do now https://novapharmanews.com/uploads/articles/eu-pharma-package-exclusivity-timelines-what-innovators-can-do-now.webp EU Pharma Package exclusivity timelines: what innovators can do now https://novapharmanews.com/us/news/biotechs-coming-of-age-ai-capital-efficiency-china 2026-06-17T22:01:39.963Z NovaPharmaNews en 2026-06-17T04:21:05.361Z Biotech’s coming of age: AI, capital efficiency and China reshape the field https://novapharmanews.com/uploads/articles/biotechs-coming-of-age-ai-capital-efficiency-china.webp Biotech’s coming of age: AI, capital efficiency and China reshape the field https://novapharmanews.com/us/news/edgewise-therapeutics-edg-7500-phase-2-cirrus-hcm-test 2026-06-17T15:41:15.863Z NovaPharmaNews en 2026-06-16T22:28:18.759Z Edgewise Therapeutics’ EDG-7500 clears key Phase 2 test EDG-7500, hypertrophic cardiomyopathy, obstructive HCM, cardiac diastolic dysfunction https://novapharmanews.com/uploads/articles/edgewise-therapeutics-edg-7500-phase-2-cirrus-hcm-test.webp Edgewise Therapeutics’ EDG-7500 clears key Phase 2 test https://novapharmanews.com/us/news/celiac-disease-new-era-therapeutic-innovation 2026-06-17T10:32:57.662Z NovaPharmaNews en 2026-06-16T20:34:45.158Z Celiac disease therapies enter a new era of innovation Celiac disease https://novapharmanews.com/uploads/articles/celiac-disease-new-era-therapeutic-innovation.webp Celiac disease therapies enter a new era of innovation https://novapharmanews.com/us/news/fda-approves-otc-rextovy-broadening-naloxone-access-opioid-overdose 2026-06-17T15:41:15.759Z NovaPharmaNews en 2026-06-16T20:34:25.463Z FDA approves OTC Rextovy, broadening naloxone access for opioid overdose naloxone, naloxone hydrochloride, Rextovy, opioid overdose https://novapharmanews.com/uploads/articles/fda-approves-otc-rextovy-broadening-naloxone-access-opioid-overdose.webp FDA approves OTC Rextovy, broadening naloxone access for opioid overdose https://novapharmanews.com/us/news/neumora-navacaprant-fails-phase-3-engene-cuts-50-percent-of-staff 2026-06-17T12:51:45.960Z NovaPharmaNews en 2026-06-16T18:41:55.159Z Neumora navacaprant fails Phase 3 as EnGene cuts 50% of staff navacaprant, depression https://novapharmanews.com/uploads/articles/neumora-navacaprant-fails-phase-3-engene-cuts-50-percent-of-staff.webp Neumora navacaprant fails Phase 3 as EnGene cuts 50% of staff https://novapharmanews.com/us/news/global-hematology-trials-patient-centered-regionally-relevant 2026-06-17T12:51:21.166Z NovaPharmaNews en 2026-06-16T12:08:52.407Z Global hematology trials keep research patient-centered and regionally relevant hematological malignancy, cancer https://novapharmanews.com/uploads/articles/global-hematology-trials-patient-centered-regionally-relevant.webp Global hematology trials keep research patient-centered and regionally relevant https://novapharmanews.com/us/news/lilly-early-jak-data-myelofibrosis-competes-with-jakafi 2026-06-17T19:17:00.959Z NovaPharmaNews en 2026-06-16T02:07:00.989Z Lilly’s early JAK data raises myelofibrosis competition question Jakafi, tirzepatide, myelofibrosis, Nonalcoholic https://novapharmanews.com/uploads/articles/lilly-early-jak-data-myelofibrosis-competes-with-jakafi.webp Lilly’s early JAK data raises myelofibrosis competition question https://novapharmanews.com/us/news/fda-authorizes-emergency-pet-treatment-new-world-screwworm 2026-06-17T08:09:54.663Z NovaPharmaNews en 2026-06-16T01:03:44.020Z FDA authorizes emergency pet treatment for New World screwworm NexGard, NexGard COMBO, New World screwworm, NWS myiasis https://novapharmanews.com/uploads/articles/fda-authorizes-emergency-pet-treatment-new-world-screwworm.webp FDA authorizes emergency pet treatment for New World screwworm